Cargando…

Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China

Objective The aim of this study was to investigate the cost-effectiveness of Helicobacter pylori (H. pylori) screening and eradication treatment in an asymptomatic population in China and to explore the most cost-effective screening protocol for H. pylori. Method We used TreeAge 2019 to construct Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Tianyu, Zheng, Zhou, Xu, Jiaying, Cao, Peng, Gao, Shang, Yu, Xihe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408128/
https://www.ncbi.nlm.nih.gov/pubmed/36011621
http://dx.doi.org/10.3390/ijerph19169986
_version_ 1784774531537174528
author Feng, Tianyu
Zheng, Zhou
Xu, Jiaying
Cao, Peng
Gao, Shang
Yu, Xihe
author_facet Feng, Tianyu
Zheng, Zhou
Xu, Jiaying
Cao, Peng
Gao, Shang
Yu, Xihe
author_sort Feng, Tianyu
collection PubMed
description Objective The aim of this study was to investigate the cost-effectiveness of Helicobacter pylori (H. pylori) screening and eradication treatment in an asymptomatic population in China and to explore the most cost-effective screening protocol for H. pylori. Method We used TreeAge 2019 to construct Markov models to assess the direct healthcare costs and quality-adjusted life years (QALYs) and the cost per year of life saved (YoLS) of three therapies, i.e., annual, triennial and five-yearly H. pylori screening. Excess probabilities were derived from published high quality studies and Meta-analyses, and costs and utilities were derived from the Chinese Yearbook of Health Care Statistics and published studies. Incremental cost-effectiveness ratios (ICERs) were used to describe the results. The willingness-to-pay threshold was set at China’s Gross National Product per capita. Result In the asymptomatic population, the ICER per QALYs gained was US$1238.47 and US$1163.71 for every three and five years of screening compared to the annual screening group; the ICER per YoLS gained was US$3067.91 and US$1602.78, respectively. Conclusion Screening for H. pylori in asymptomatic populations in China and eradicating treatment for those who test positive is cost-effective. Increasing screening participation in asymptomatic populations is more effective than increasing the frequency of screening. From a national payer perspective, it is cost-effective to screen the general asymptomatic population in China for H. pylori and to eradicate those who test positive. Individuals need to choose a screening programme that they can afford according to their financial situation.
format Online
Article
Text
id pubmed-9408128
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94081282022-08-26 Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China Feng, Tianyu Zheng, Zhou Xu, Jiaying Cao, Peng Gao, Shang Yu, Xihe Int J Environ Res Public Health Article Objective The aim of this study was to investigate the cost-effectiveness of Helicobacter pylori (H. pylori) screening and eradication treatment in an asymptomatic population in China and to explore the most cost-effective screening protocol for H. pylori. Method We used TreeAge 2019 to construct Markov models to assess the direct healthcare costs and quality-adjusted life years (QALYs) and the cost per year of life saved (YoLS) of three therapies, i.e., annual, triennial and five-yearly H. pylori screening. Excess probabilities were derived from published high quality studies and Meta-analyses, and costs and utilities were derived from the Chinese Yearbook of Health Care Statistics and published studies. Incremental cost-effectiveness ratios (ICERs) were used to describe the results. The willingness-to-pay threshold was set at China’s Gross National Product per capita. Result In the asymptomatic population, the ICER per QALYs gained was US$1238.47 and US$1163.71 for every three and five years of screening compared to the annual screening group; the ICER per YoLS gained was US$3067.91 and US$1602.78, respectively. Conclusion Screening for H. pylori in asymptomatic populations in China and eradicating treatment for those who test positive is cost-effective. Increasing screening participation in asymptomatic populations is more effective than increasing the frequency of screening. From a national payer perspective, it is cost-effective to screen the general asymptomatic population in China for H. pylori and to eradicate those who test positive. Individuals need to choose a screening programme that they can afford according to their financial situation. MDPI 2022-08-13 /pmc/articles/PMC9408128/ /pubmed/36011621 http://dx.doi.org/10.3390/ijerph19169986 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Feng, Tianyu
Zheng, Zhou
Xu, Jiaying
Cao, Peng
Gao, Shang
Yu, Xihe
Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China
title Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China
title_full Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China
title_fullStr Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China
title_full_unstemmed Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China
title_short Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China
title_sort cost-effectiveness analysis of the helicobacter pylori screening programme in an asymptomatic population in china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408128/
https://www.ncbi.nlm.nih.gov/pubmed/36011621
http://dx.doi.org/10.3390/ijerph19169986
work_keys_str_mv AT fengtianyu costeffectivenessanalysisofthehelicobacterpyloriscreeningprogrammeinanasymptomaticpopulationinchina
AT zhengzhou costeffectivenessanalysisofthehelicobacterpyloriscreeningprogrammeinanasymptomaticpopulationinchina
AT xujiaying costeffectivenessanalysisofthehelicobacterpyloriscreeningprogrammeinanasymptomaticpopulationinchina
AT caopeng costeffectivenessanalysisofthehelicobacterpyloriscreeningprogrammeinanasymptomaticpopulationinchina
AT gaoshang costeffectivenessanalysisofthehelicobacterpyloriscreeningprogrammeinanasymptomaticpopulationinchina
AT yuxihe costeffectivenessanalysisofthehelicobacterpyloriscreeningprogrammeinanasymptomaticpopulationinchina